Bayer (BAYN) PT Set at €115.00 by Deutsche Bank

Deutsche Bank set a €115.00 ($133.72) price objective on Bayer (FRA:BAYN) in a report published on Friday morning. The firm currently has a buy rating on the healthcare company’s stock.

BAYN has been the subject of several other research reports. Sanford C. Bernstein set a €115.00 ($133.72) price target on shares of Bayer and gave the company a buy rating in a research report on Wednesday, September 5th. JPMorgan Chase & Co. reissued a buy rating on shares of Bayer in a research report on Thursday, November 29th. Cfra set a €100.00 ($116.28) price target on shares of Bayer and gave the company a buy rating in a research report on Tuesday, August 14th. Goldman Sachs Group set a €111.00 ($129.07) price target on shares of Bayer and gave the company a buy rating in a research report on Thursday, October 11th. Finally, Independent Research set a €85.00 ($98.84) price target on shares of Bayer and gave the company a neutral rating in a research report on Wednesday, September 5th. Six research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of €90.80 ($105.58).

Shares of FRA BAYN opened at €63.43 ($73.76) on Friday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: SEC Filing

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply